Media › NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimers Disease at the International Conference on Alzheimers and Parkinsons Diseases (AD/PD 2025)
 
 

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimers Disease at the International Conference on Alzheimers and Parkinsons Diseases (AD/PD 2025)

2025-04-27 12:45:03| Spiritual Career Counseling

April 07, 2025 08:05 ET | Source: NKGen Biotech, Inc. Moderate Alzheimers disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who completed 17 doses improved from moderate to mild AD within just 3 months. One patient stabilized at their improved score, while the other patient continued to show ongoing improvement. Clinical development of troculeucel is ongoing and will be evaluated for safety and efficacy in the randomized, placebo-controlled Phase 2a part of the study. SANTA ANA, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced the oral presentation of updated Phase 1 clinical data from the Phase 1/2a trial evaluating troculeucel, cryopreserve...


Category: Employment

 

Latest from this category

All news
»
13.12Salah's farewell? If this was his final Liverpool chapter, he delivered a fitting end
13.12Blackhawks recall Lardis following Bedard injury
13.12Hawks' Young should return to practice next week
13.12Cowboys keep CB Diggs on IR for Vikings game
13.12Source: U-M launches athletic department query
13.12Live updates from NBA Cup semifinals between Magic-Knicks, Spurs-Thunder in Vegas
13.12Follow live: Army, Navy vie for Commander-In-Chief's Trophy as rivals meet in Baltimore
13.12Salah makes EPL history on Liverpool return
More »